Healthcare Professional Area
Erdotin

More about Erdotin

The theoretical model below shows the vicious cycle of exacerbation in COPD. Each of the factors in the cycle below can lead to the next. For example an initiating trigger, such as smoking, can lead to the hypersecretion of mucus and impaired mucociliary clearance. Consequently bacteria begin to accumulate and colonise within the lungs, leading to epithelial damage and the initiation of an inflammatory response and increased oxidative stress.

Erdotin is the first new mucolytic licensed in the UK and Ireland for over 25 years1 for the treatment of productive cough in acute bronchitic exacerbations of COPD.2

The vicious cycle of exacerbation in COPD: a theoretical model

Erdotin impacts on the vicious cycle by:

  • Demonstrating a synergistic effect with antibiotics3,4
  • Reducing oxidative stress2,5-7
  • Reducing expectoration volume4,8,9
  • Improving mucociliary clearance8

Click here to download the low resolution video 'The vicious cycle' (Format: wmv. File size: 1.77Mb. This can take up to 6 minutes to download on a 56Kbps dial-up connection)

Click here to download the high resolution video 'The vicious cycle' (Format: wmv. File size: 2.27Mb. This can take up to 8 minutes to download on a 56Kbps dial-up connection)

Erdotin demonstrates a synergistic effect with antibiotics3,4

Erdotin at least doubles the symptom resolution when combined with amoxicillin compared with amoxicillin alone, with a significant improvement seen by day 3.3

226 patients with chronic obstructive bronchitis in exacerbation phase treated with either amoxicillin 500mg tid and Erdotin 300mg bd or amoxicillin 500mg tid and placebo3

226 patients with chronic obstructive bronchitis in exacerbation phase treated with either amoxicillin 500mg tid and Erdotin 300mg bd or amoxicillin 500mg tid and placebo3

At study end, physicians favoured Erdotin (p<0.01)3

  • Erdotin and amoxicillin – physicians reported a 80% improvement3
  • Placebo and amoxicillin – physicians reported a 55% improvement3

Click here to download the video 'Erdotin plus antibiotics - a synergistic effect' (Format: wmv. File size: 2.78Mb. This can take up to 10 minutes to download on a 56Kbps dial-up connection)

Erdotin significantly reduces severity and frequency of cough10

Results from a study of 27 patients with acute exacerbation of chronic bronchitis treated with Erdotin 300mg bd or placebo10

  • Erdotin is 2.5 times more effective than placebo at reducing cough severity10
  • Erdotin is 3 times more effective than placebo at reducing cough frequency10

Click here to download the video 'How can Erdotin improve my patient's cough?'
(Format: wmv. File size: 1.77Mb. This can take up to 6 minutes to download on a 56Kbps dial-up connection)

References

Back to Top
  1. Galen: Data on file
  2. Erdotin 300mg Capsules Summary of Product Characteristics
  3. Marchioni CF, Polu JM, Taytard A, Hanard T, Noseda D, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33(11): 612-618.
  4. Mohanty KC, Thiappanna G, Singh V, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. J Clin. Research. 2001; 4: 35-39
  5. Mitrea M, Silvestro L, Savu S and Mancini C. Reduced (GSH) and oxidised (GSSG) levels in plasma and BAL of chronic bronchitic patients treated with erdosteine or N-acetylcisteine (NAC). Abstract presented at 6th Int Conference on Bronchoalveolar lavage; 1998 June 24-27; Corfu (Greece)
  6. Mancini C, Silvestro L and Savu S. Pilot study on erdosteine activity on reduced glutathione (GSH) plasmatic levels in correlation with levels of the mother compound and main metabolite (N-thiodiglycolylhomocysteine). Abstract presented at 4th European Congress of Pharmaceutical Sciences; 1998 Sept 11-13; Milan (Italy)
  7. Dal Negro, Visconti M, Micheletto C, Tognella S. Antioxidant effects of erdosteine in current smokers with mild COPD (Gold Class 0-2). Eur. Resp. Soc. Ann. Congress. 2006 September 2–6; Munich (Germany)
  8. Tellings JC. Erdosteine: original secretolytic drug with mucociliar activity: a controlled clinical study versus ambroxol. Medical Praxis. 1991, 12(4):183-95
  9. Busin S, Clerici R, Nitti F. Erdosteine: evaluation of mucorheological and immunosecretory parameters in patients with bronchial phlogistic pathology. Medical Praxis. 1991; 12(4): 197-205
  10. Bisetti A, Macini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo. Archivo di Medicina. Interna 1995; XLVII(4): 89-9

PMR – NOV – 2006 – 0241

* Bisetti A, Macini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo. Archivo di Medicina. Interna 1995; XLVII(4): 89-97
Marchioni CF, Polu JM, Taytard A, Hanard T, Noseda D, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33(11): 612-618